

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

### 1. IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY

Product Name: LEXSYcon2.1 Expression Kit  
Catalog Number: EGE-1310ble  
Supplier: Jena Bioscience GmbH  
Loebstedter Strasse 71  
07749 Jena, Germany  
Telephone: +49 - 3641 - 62 85 000  
Fax: +49 - 3641 - 62 85 100  
E-Mail: [info@jenabioscience.com](mailto:info@jenabioscience.com)  
Www: <http://www.jenabioscience.com>

### 2. HAZARDS IDENTIFICATION

#### GHS classification according to Regulation (EC) No 1272/2008

Skin Irrit. 2; H315  
Eye Irrit. 2; H319  
STOT SE 3; H335  
Skin Sens. 1; H317  
Resp. Sens. 1; H334  
Muta 2; H341

#### GHS Label elements:

Pictogram:



Signal word: Danger

#### Hazard statements:

H315: Causes skin irritation.  
H317: May cause an allergic skin reaction.  
H319: Causes serious eye irritation.  
H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H335: May cause respiratory irritation.  
H341: Suspected of causing genetic defects.

#### Precautionary statements:

P261: Avoid breathing vapors.  
P264: Wash hands thoroughly after handling.  
P280: Wear protective gloves / protective clothing / eye protection.  
P285: In case of inadequate ventilation wear respiratory protection.  
P301 + P312: IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell.

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

P302 + P352:	IF ON SKIN: Wash with plenty of soap and water.
P304 + P341:	IF INHALED: If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing.
P333 + P313:	If skin irritation or rash occurs: Get medical advice / attention.
P305 + P351 + P338:	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P342 + P311:	If experiencing respiratory symptoms: Call a POISON CENTER or doctor.




### Additional information:

Laboratory chemicals must be handled only by qualified personnel and with precaution.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Mixtures / Hazardous components:

The kit contains the following components:

Ingredient Name	CAS #	Pictogram	H-Phrase	P-Phrase	C (max)	Amount
LT-101, LEXSY host L. tarentolae strain P10	-	-	-	-	75 %	3 x 1.6 ml
Expression vector EGE-271 (pLEXSY_ble2.1)	-	-	-	-	10 %	5 µg
Primer set PM-101, PM-104, PM-105, PM-107, PM-110, PM-111	-	-	-	-	50 µM each	50 µl each
ML-412, LEXSY BHI (powder)	-		H315, H319, H335	P280 P302+P352 P304+P341 P305+P351+P338	100 %	2 x 18.5 g
AB-103S, LEXSY BLEO (Phleomycin D1)	11006-33- 0		H341	P264, P280 P301 + P312	10 %	1 ml
ML-108, Hemin (porcine)	16009-13- 5	-	-	-	0.25 %	2 ml
ML-108, Triethanolamine	102-71-6				30 %	
ML-105 Penicillin G sodium salt	69-57-8		H317, H334	P261, P280, P285 P304 + P341 P333 + P313 P342 + P311	1.5 %	5 ml
ML-105 Streptomycin sulfate	3810-74-0				1.5 %	

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

### 4. FIRST AID MEASURES

**General advice:** Consult a physician. Show this material safety data sheet to the doctor in attendance.

**After skin contact:** Immediately wash skin with soap and plenty of water. Consult a physician. Desinfect component 1, *L. tarentolae*.

**After swallowing:** Never give anything by mouth to an unconscious person. Rinse mouth with water provided person is conscious. Consult a physician.

**After inhalation:** Remove to fresh air. If not breathing give artificial respiration. Consult a physician.

**After eye contact:** Immediately flush eyes with plenty of water for at least 15 minutes. Consult a physician.

### 5. FIRE-FIGHTING MEASURES

**Suitable extinguishing media:** Use water spray, carbon dioxide, dry chemical powder or appropriate foam.

**Specific hazards arising from the chemical:** Hazardous decomposition products formed under fire conditions; carbon oxides, nitrogen oxides, iron oxides and hydrogen chloride gas.

**Special Firefighting Procedures:** Wear self-contained breathing apparatus for firefighting if necessary.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions:** Wear protective equipment. Keep unprotected persons away. Avoid dust formation. Wash contaminated clothing before reuse.

**Environmental precautions:** Do not let product enter drains.

**Method for Cleaning Up:** Keep in suitable, closed containers for disposal. Dispose contaminated material as waste according to section 13. Ventilate area, clean and disinfect spill site after material clean-up is complete. For Kit component ML-105: Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).

### 7. HANDLING AND STORAGE

**Handling:** Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Prevent formation of dust (LEXSY BHI powder).

**User Exposure:** Avoid inhalation. Use personal protective equipment (i.e. impermeable gloves, lab coat or apr.).

**Storage:** Keep tightly closed. Store as indicated (according to section 10) at RT / 4°C / -20°C / -80°C, protect from light. Store away from food.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Engineering Measures:** Ensure adequate ventilation and cleanable resistant tightly sealed working surfaces.

**Respiratory protection:** In case of insufficient ventilation wear suitable respiratory equipment. Use a dust mask for handling LEXSY BHI powder. Kit component AB-103: Required if aerosols can be formed. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

**Hand protection:** Handle with gloves to prevent skin contact.

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

**Eye protection:** Wear chemical safety goggles to prevent eye contact.

**Skin and body protection:** Complete suit protecting against chemicals. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

**General Hygiene measures:** Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

The Kit consists of 12 components (according to section 3)

#### Appearance:

Form: powder / frozen / liquid  
Color: beige / colorless / dark aubergine / blue

#### Safety data:

pH: pH 6, pH 8, pH 10  
Melting point: No data available  
Boiling point: 100°C; N/A.  
Flash point: No data available  
Ignition temperature: No data available  
Thermal decomposition: No data available  
Self-igniting: No data available  
Danger of explosion: No data available  
Vapor pressure: No data available  
Solubility in / Miscibility with water: 37 g/L in water (BHI powder)  
Segregation coefficient  
(n-octanol / water): No data available  
Viscosity, dynamic: No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical stability:** Stable under recommended storage conditions at room temperature for 10 years (Brain Heart Infusion powder (LEXSY BHI powder)), at 4°C for 12 months in the dark (ML-108), at -20°C for 12 months (PM-101, PM-104, PM-105, PM-107, PM-110, PM-111, AB-103, ML-105) and at -80°C for 12 months (LT-101).

**Possibility of hazardous reactions:** No data available

**Conditions to avoid:** Heat, strong oxidizing agents, strong acids, high or low pH, sodium hypochlorite.

**Incompatible materials:** Strong oxidizing agents, strong bases.

#### Hazardous decomposition products:

Kit component ML-108: Thermal decomposition can lead to release of irritating gases and vapors such as carbon oxides.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006



## LEXSYcon2.1 Expression Kit

with plasmid pLEXSY\_ble2.1 (EGE-271)

### 11. TOXICOLOGICAL INFORMATION

For detailed description, refer to the respective MSDS of components (Cat.-No. AB-103, ML-105 and ML-108).

#### Acute toxicity:

Kit component AB-103 (LEXSY BLEO):

LD50 oral: 645 mg/kg rat  
Remarks: Behavioral: Altered sleep time (including change in righting reflex). Behavioral: Convulsions or effect on seizure threshold. Lungs, Thorax, or Respiration: Dyspnea.

Kit component ML-108 (Hemin):

LD50 oral: 30g/kg rat

Chronic exposure may cause nausea and vomiting, higher exposure causes unconsciousness.

#### Signs / Symptoms of exposure:

Kit component AB-103:

Convulsions or effect on seizure threshold. Lungs, Thorax, or Respiration: Dyspnea. Behavioral: Altered sleep time including change in righting reflex

Kit component ML-108:

Local effects: Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting. Specific effects: May include moderate to severe erythema (redness) and moderate edema (raised skin), nausea, vomiting, headache.

#### Skin corrosion/irritation:

No data available

#### Serious eye damage/irritation:

No data available

#### Respiratory or skin sensitization:

Kit component LEXSY BHI powder:

May be harmful if inhaled. Material is irritating to mucous membranes and upper respiratory tract.

Kit component ML-105:

Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. May cause allergic skin reactions.

#### Germ cell mutagenicity:

Kit component AB-103:

Laboratory experiments have shown mutagenic effects.

Genotoxicity in vitro - Human - leukocyte, other mutation test systems;

Genotoxicity in vitro - Human - leukocyte, cytogenetic analysis; Genotoxicity

in vitro - mouse - ovary, cytogenetic analysis; Genotoxicity in vivo - mouse -

subcutaneous, cytogenetic analysis

#### Carcinogenicity:

No data available

#### Reproductive toxicity:

No data available

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

**Additional information:**

RTECS: No data available (LEXSY BHI)  
RTECS: SY0525000 (LEXSY BLEO)  
RTECS: No data available (Hemin)  
RTECS: KL9275000 (Triethanolamine)  
RTECS: WK4990000 (Streptomycin sulfate)  
RTECS: XH9800000 (Penicillin G sodium salt)

### 12. ECOLOGICAL INFORMATION

**Ecotoxicity:** No data available

**Persistence and degradability:** Biodegradability (Triethanolamine), BHI media and DNA preparations are degradable.

**Bioaccumulative potential:** No data available

**Mobility in soil:** No data available

**General notes:** Kit component LEXSY BHI powder and ML-105: Generally not hazardous for water.  
Kit component ML-108: May cause long-term adverse effects in the aquatic environment. Do not flush into surface water or sanitary sewer system.

**Results of PBT and vPvB assessment:**

PBT: No data available

vPvB: No data available

### 13. DISPOSAL CONSIDERATIONS

**Product:** Observe all federal, state and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material. The material for disposal should be mixed with, or dissolved in, a combustible solvent and burnt in a chemical incinerator equipped with an afterburner scrubber. BHI media, cultures and DNA preparations can be autoclaved (20 min 121°C) and disposed of together with household garbage.

**Contaminated Packaging:** Kit component LEXSY BHI powder and ML-108: Dispose of as unused product. Kit component ML-105: Disposal must be made according to official regulations.

**Cleansing agents:** Kit component ML-105: Water, if necessary together with cleansing agents.

### 14. TRANSPORT INFORMATION

**ADR/RID:** Not dangerous goods

**DOT (US):** Not dangerous goods

**IMDG:** Not dangerous goods

**IATA:** Not dangerous goods

### 15. REGULATORY INFORMATION

**OSHA Hazards for Kit component AB-103:** Target Organ Effect. Harmful by ingestion. Mutagen.

# LEXSYcon2.1 Expression Kit

## with plasmid pLEXSY\_ble2.1 (EGE-271)

This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

### 15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture:

No data available

### 15.2 Australian Inventory of Chemical Substances in LEXSY BHI powder:

CAS #	Substances
7647-14-5	Sodium chloride
7558-79-4	Sodium phosphate, dibasic
50-99-7	Dextrose

### 15.3 Chemical Safety Assessment: No data available

### 15.4 Information for Kit component AB-103:

This product contains the following components that are not on the Canadian DSL nor NDSL lists:  
Zeocin™ CAS number 11006-33-0

## 16. OTHER INFORMATION

This material is sold for research purposes only and is not required to appear on the TSCA inventory. It is not intended for food, drug, household, agricultural or cosmetic use. Its use must be supervised by a technically qualified individual experienced in handling potentially hazardous chemicals. Users should make independent decisions regarding completeness of the information based on all sources available.

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product.

Jena Bioscience GmbH shall not be held liable for any damage resulting from handling or from contact with the above product. See our website for our terms and conditions of sales.